Cerebrospinal fluid (CSF) and blood neurofilaments (NFLs) are markers of axonal damage and are being investigated, mostly in relapsing-remitting (RR) MS, as a marker of disease activity and of response to treatment, while there are less data in progressive MS patients. Primary aim was to measure NFL in plasma samples of untreated patients with primary (PP) and secondary (SP) progressive MS and to correlate them with disability, disease severity, and prior/subsequent disability progression
Neurological biomarkers are particularly valuable to clinicians as they can be used for diagnosis, p...
BACKGROUND: Axonal damage is considered a major cause of disability in multiple sclerosis (MS) an...
In patients with slowly progressive spastic paraparesis, the differential diagnosis of primary progr...
Cerebrospinal fluid (CSF) and blood neurofilaments (NFLs) are markers of axonal damage and are being...
There is an unmet need in multiple sclerosis (MS) therapy for treatments to stop progressive disabil...
Primary and secondary progressive forms of multiple sclerosis (PPMS and SPMS) have different path- o...
Background. Disability in multiple sclerosis (MS) is related to neuroaxonal degeneration. A reliable...
Background: There is a need for clinically useful biomarkers of disease activity in clinically isola...
A major aim in MS field has been the search for biomarkers that enable accurate detection of neurona...
Neurofilaments are neuronal-specific proteins involved in neuroaxonal functions like determining axo...
BACKGROUND: Neurofilament proteins have been extensively studied in relapsing-remitting multiple scl...
Biomarkers of axonal degeneration have the potential to improve our capacity to predict and monitor ...
Abstract While neurofilament light chain (NfL) measurement in serum is a well-established marker of ...
See Giovannoni (doi:10.1093/brain/awy200) for a scientific commentary on this article. Biomarkers of...
Neurofilaments are the major structural proteins of the neuronal cytoskeleton and are classified acc...
Neurological biomarkers are particularly valuable to clinicians as they can be used for diagnosis, p...
BACKGROUND: Axonal damage is considered a major cause of disability in multiple sclerosis (MS) an...
In patients with slowly progressive spastic paraparesis, the differential diagnosis of primary progr...
Cerebrospinal fluid (CSF) and blood neurofilaments (NFLs) are markers of axonal damage and are being...
There is an unmet need in multiple sclerosis (MS) therapy for treatments to stop progressive disabil...
Primary and secondary progressive forms of multiple sclerosis (PPMS and SPMS) have different path- o...
Background. Disability in multiple sclerosis (MS) is related to neuroaxonal degeneration. A reliable...
Background: There is a need for clinically useful biomarkers of disease activity in clinically isola...
A major aim in MS field has been the search for biomarkers that enable accurate detection of neurona...
Neurofilaments are neuronal-specific proteins involved in neuroaxonal functions like determining axo...
BACKGROUND: Neurofilament proteins have been extensively studied in relapsing-remitting multiple scl...
Biomarkers of axonal degeneration have the potential to improve our capacity to predict and monitor ...
Abstract While neurofilament light chain (NfL) measurement in serum is a well-established marker of ...
See Giovannoni (doi:10.1093/brain/awy200) for a scientific commentary on this article. Biomarkers of...
Neurofilaments are the major structural proteins of the neuronal cytoskeleton and are classified acc...
Neurological biomarkers are particularly valuable to clinicians as they can be used for diagnosis, p...
BACKGROUND: Axonal damage is considered a major cause of disability in multiple sclerosis (MS) an...
In patients with slowly progressive spastic paraparesis, the differential diagnosis of primary progr...